Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma

被引:39
作者
Kroeger, Nicolaus [1 ]
Zagrivnaja, Maria [1 ]
Schwartz, Sabine [1 ]
Badbaran, Anita [1 ]
Zabelina, Tatjana [1 ]
Lioznov, Michael [1 ]
Ayuk, Francis [1 ]
Zander, Axel [1 ]
Fehse, Boris [1 ]
机构
[1] Univ Hamburg, Med Ctr, Bone Marrow Transplantat, D-20246 Hamburg, Germany
关键词
D O I
10.1016/j.exphem.2006.01.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To investigate lineage-specific chimerism of plasma cells after allogeneic transplantation by real-time PCR based on bi-allelic sequence polymorphism or, in case of female-to-male transplantation, on the detection of the DFFRY gene and to determine its value to quantify minimal residual disease in myeloma patients. Methods. Forty-eight samples from bone marrow samples and peripheral blood from 34 non-myeloma patients were analyzed at different times after transplantation. Sixty-two samples from 22 myeloma patients were analyzed at different times after allogeneic stem cell transplantation, and results were compared with immuno,fixation and, in some cases, with PCR data using patient-specific primers. Results. The median chimerism for T cells at day +100 was greater than 99.9% and remained stable on day +180 and 1 year after transplantation. In contrast, the median donor plasma cell chimerism at day +100 was 95.5%, at day +180 98.6%, at day +360 99.8%, and 2 or more years after transplantation greater than 99.9%. Sensitivity of real-time PCR using human short insertion/deletion polymorphisms (SIDP) was 10(-4) and in case of Y-PCR 10(-5). Sequential monitoring of donor plasma cell chimerism showed that increasing and stable chimerism were associated with ongoing remission in 15 out of 16 samples (93%), and decreases in chimerism predicted relapse in 5 out of 6 patients. Conclusion. We conclude that plasma cell chimerism after allogeneic stem cell transplantation is delayed in comparison to T-cell chimerism. Sequential quantitative measurement of plasma cells after allogeneic stem cell transplantation with highly sensitive real-time PCR allows monitoring of residual host-tumor cells in patients with multiple myeloma and allows guiding adoptive immunotherapy strategies to enhance remission status and to prevent clinical relapse. (c) 2006 International Society for Experimental Hematology. Published by Elsevier Inc.
引用
收藏
页码:688 / 693
页数:6
相关论文
共 26 条
[11]   Real-time quantitative y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation [J].
Fehse, B ;
Chukhlovin, A ;
Kühlcke, K ;
Marinetz, O ;
Vorwig, O ;
Renges, H ;
Krüger, W ;
Zabelina, T ;
Dudina, O ;
Finckenstein, FG ;
Kröger, N ;
Kabisch, H ;
Hochhaus, A ;
Zander, AR .
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2001, 10 (03) :419-425
[12]   Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation [J].
Galimberti, S ;
Benedetti, E ;
Morabito, F ;
Papineschi, F ;
Callea, V ;
Fazzi, R ;
Stelitano, C ;
Andreazzoli, F ;
Guerrini, F ;
Ciabatti, E ;
Martino, M ;
Nobile, F ;
Iacopino, P ;
Petrini, M .
LEUKEMIA RESEARCH, 2005, 29 (08) :961-966
[13]   Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation [J].
Griffith, LM ;
McCoy, JP ;
Bolan, CD ;
Stroncek, DF ;
Pickett, AC ;
Linton, GF ;
Lundqvist, A ;
Srinivasan, R ;
Leitman, SF ;
Childs, RW .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (05) :668-675
[14]   Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma [J].
Kröger, N ;
Shimoni, A ;
Zagrivnaja, M ;
Ayuk, F ;
Lioznov, M ;
Schieder, H ;
Renges, H ;
Fehse, B ;
Zabelina, T ;
Nagler, A ;
Zander, AR .
BLOOD, 2004, 104 (10) :3361-3363
[15]   Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality [J].
Kröger, N ;
Sayer, HG ;
Schwerdtfeger, R ;
Kiehl, M ;
Nagler, A ;
Renges, H ;
Zabelina, T ;
Fehse, B ;
Ayuk, F ;
Wittkowsky, G ;
Schmitz, N ;
Zander, AR .
BLOOD, 2002, 100 (12) :3919-3924
[16]   Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma [J].
Kröger, N ;
Schwerdtfeger, R ;
Kiehl, M ;
Sayer, HG ;
Renges, H ;
Zabelina, T ;
Fehse, B ;
Tögel, F ;
Wittkowsky, G ;
Kuse, R ;
Zander, AR .
BLOOD, 2002, 100 (03) :755-760
[17]  
LAWLER M, 1991, BLOOD, V77, P2504
[18]   The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma [J].
Lokhorst, HM ;
Wu, KL ;
Verdonck, LF ;
Laterveer, LL ;
Van de Donk, NWCJ ;
van Oers, MHJ ;
Cornelissen, JJ ;
Schattenberg, AV .
BLOOD, 2004, 103 (11) :4362-4364
[19]   Dissociation of putative graft-versus-haematopoiesis and graft-versus-myeloma effects in patients with rapidly progressive multiple myeloma [J].
Luft, T ;
Moos, M ;
Goldschmidt, H ;
Ho, AD ;
Görner, M .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (04) :646-653
[20]   Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms [J].
Maas, F ;
Schaap, N ;
Kolen, S ;
Zoetbrood, A ;
Buño, I ;
Dolstra, H ;
de Witte, T ;
Schattenberg, A ;
van de Wiel-van Kemenande, E .
LEUKEMIA, 2003, 17 (03) :621-629